Breaking News: Human BioSystems to Receive U.S. Patent for Organ Preservation.

PALO ALTO, Calif. -- Human BioSystems (OTCBB:HBSC), developer of preservation platforms for organs and other biomaterials, announces today that the U.S. Patent Office has notified Human BioSystems (HBS) that it will issue a patent for organ preservation entitled "METHODS AND SOLUTIONS FOR STORING DONOR ORGANS".

"This patent, using the HBS proprietary solutions and process for storing and preserving donor organs such as kidneys, livers and hearts, encompasses the full spectrum of storage temperatures from refrigeration to well below the freezing point of water," explained Dr. Luis Toledo, Chief Medical Officer for HBS. "We are very pleased that a patent as significant as this one will be issued in the relatively short timeframe from our initial application," continued Dr. Toledo.

Other U.S. patents granted to the company include "METHOD AND APPARATUS FOR PRESERVING BIOLOGICAL MATERIALS" (U.S. Patent No. 6,413,713) issued on July 2nd,, 2002, and "METHODS AND APPARATUSES FOR PRESERVING PLATELETS" (U.S. Patent No. 6,828,090) issued on December 7th, 2004.

Dr. David Winter, HBS President, concluded by stating, "This most recent patent to be granted and the ones we have been issued to date are important steps toward giving us the confidence and intellectual property protection we need to actively pursue discussions with potential strategic alliance partners that are capable of helping us take our technology and company to the next level."

HBS is headquartered in Palo Alto, California with research facilities in Michigan.

Certain statements contained herein are "forward-looking'' statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, results from ongoing research and development as well as clinical studies, failure to obtain regulatory approval for the Company's products, if required, failure to develop a product based on the Company's technology, failure of any such products to compete effectively with existing products, the inability to find a strategic partner or to consummate a relationship with a potential strategic partner on acceptable terms, and other factors discussed in filings made by the Company with the Securities and Exchange Commission.

Human BioSystems (OTC Bulletin Board:HBSC)